Tymon-Rosario JR, Manara P, Manavella DD, Bellone S, et al. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor. Gynecol Oncol 2022 May 19. pii: S0090-8258(22)00305.
PMID: 35599167